You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
心通醫療-B(02160.HK)對Valcare追加投資248.25萬美元
格隆匯 07-22 22:48

格隆匯7月22日丨心通醫療-B(02160.HK)宣佈,根據Valcare與公司於近期訂立的協議,公司同意對Valcare作出248.25萬美元的追加投資,有關投資受未來股權簡單協議所載條款、條文及條件的規限。追加投資金額乃經按公平原則進行的商業磋商後釐定,當中已考慮市場動態及Valcare研發計劃所需資金等因素。根據未來股權簡單協議,於追加投資完成後,公司將無權享有Valcare的任何追加股本權益,而追加投資及投資金額將視作於Valcare下一輪融資的預付投資金額。於公吿日期,Valcare下一輪融資的時間及規模尚未釐定。

Valcare的研發已加速並於近期取得重大進展。於2020年12月,Valcare成功完成首次人體經房間隔傳送Amend瓣環成形術環。 Amend期望通過更安全及更簡單的基於導管的手術提供臨牀標準護理手術治療。於公吿日期,Amend已經房間隔系統成功完成三例植入。初步結果證明MR(二尖瓣返流)大幅降低。

公司始終專注於向規模龐大但滲透不足的TMV(經導管二尖瓣)市場提供服務,通過自主研發及與全球合作伙伴(包括Valcare)的共同開發戰略性地針對所有主流可行的TVT(經導管瓣膜療法)方案。驅使公司對Valcare作出追加投資的主要原因為其近期研發的有利結果,其在研產品(即Amend、Corona及Trivid)帶來的業務協同作用及臨牀合作。公司認為Valcare的在研產品可進一步豐富公司在中國尚待開發的龐大市場的產品提供。此外,公司仍對Valcare在研產品的研發進度表示樂觀。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account